Safety of targeted therapies for treating immune-mediated inflammatory diseases

被引：0

作者：

Hoisnard, L. ^{[1
]}

Zureik, M. ^{[2
]}

Weill, A. ^{[2
]}

Dray-Spira, R. ^{[2
]}

Lebrun-Vignes, B. ^{[3
]}

Meyer, A. ^{[4
]}

Vegas, L. Pina ^{[5
]}

Claudepierre, P. ^{[5
]}

Mahevas, M. ^{[6
]}

Michel, M. ^{[6
]}

Cohen, J. L. ^{[7
]}

Maury, S. ^{[8
]}

El Karoui, K. ^{[9
]}

Wolkenstein, P. ^{[10
]}

Roy, L. ^{[11
]}

Amiot, A. ^{[12
]}

Grimbert, P. ^{[9
]}

Sbidian, E. ^{[10
]}

机构：

[1] Federat Hospitalo Univ True Innovat Therapy Immun, Hop Henri Mondor, Creteil, France

[2] French Natl Hlth Insurance, French Natl Agcy Med & Hlth Prod Safety, EpiPhare Sci Interest Grp Epidemiol Hlth Prod, St Denis, France

[3] Hop La Pitie Salpetriere, Serv Pharmacol, Paris, France

[4] Hop Bicetre, Serv Gastroenterol, Le Kremlin Bicetre, France

[5] Hop Henri Mondor, Serv Rhumatol, Creteil, France

[6] Hop Henri Mondor, Serv Med Interne, Creteil, France

[7] INSERM, Inst Mondor Rech Biomed, Creteil, France

[8] Hop Henri Mondor, Serv Dhematol, Creteil, France

[9] Hop Henri Mondor, Serv Nephrol & Transplantat, Creteil, France

[10] Hop Henri Mondor, Serv Dermatol, Creteil, France

[11] Hop Henri Mondor, Serv Dhematol Clin, Creteil, France

[12] Hop Henri Mondor, Serv GastroEnterol, Creteil, France

来源：

FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2024年 / 38卷

关键词：

French National Health Data System; immune-mediated inflammatory diseases; Janus kinase inhibitors; pharmacoepidemiology; pharmacovigilance; safety;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

TH-002

引用

页码：43 / 44

页数：2

共 50 条

[1] Immune-mediated Pathogenesis and Therapies for Inflammatory Autoimmune Diseases
Islam, Md. Asiful
Kamal, Mohammad A.
Zulfiker, Abu H. Md
Gan, Siew H.
CURRENT PHARMACEUTICAL DESIGN, 2019, 25 (27) : 2907 - 2908
[2] Treating immune-mediated diseases
Léger, JM
PRESSE MEDICALE, 2006, 35 (04): : 707 - 708
[3] Safety of Anti-TNF Therapies in Immune-Mediated Inflammatory Diseases: Focus on Infections and Malignancy
Pereira, Rui
Lago, Paula
Faria, Raquel
Torres, Tiago
DRUG DEVELOPMENT RESEARCH, 2015, 76 (08) : 419 - 427
[4] Safety of biologic and synthetic targeted therapies in patients with immune-mediated diseases: data from the BIOBADAGUAY registry
de Abreu, Paloma
Cabrera, Sonia
Cordovilla, Darwin
Roman, Lourdes
Brunengo, Cristina
Melgarejo, Patricia
Soto, Macarena
Valinotti, Vannia
Amarilla, Angelica
Acevedo, Belem
Pineda, Alexis
Leiva, Evelyn
Pusineri, Paola
Consani, Sandra
Zarza, Mariela
Parodi, Clyde
Morel, Zoilo
Rolon, Roger
Jara, Paola
Aranda, Raquel
Martinez, Laura
Avila, Gabriela
REUMATOLOGIA CLINICA, 2025, 21 (02):
[5] Research advances on targeted-Treg therapies on immune-mediated kidney diseases
Li, Yujuan
Liu, Huixia
Yan, Hao
Xiong, Jing
AUTOIMMUNITY REVIEWS, 2023, 22 (02)
[6] Genetics of immune-mediated inflammatory diseases
David, T.
Ling, S. F.
Barton, A.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2018, 193 (01): : 3 - 12
[7] Adiponectin in inflammatory and immune-mediated diseases
Fantuzzi, Giamila
CYTOKINE, 2013, 64 (01) : 1 - 10
[8] Inflammatory and Immune-Mediated Cutaneous Diseases
Quaresma, Juarez A. S.
Sotto, Mirian N.
Balato, Anna
MEDIATORS OF INFLAMMATION, 2017, 2017
[9] Reframing Immune-Mediated Inflammatory Diseases
Boutrid, Nada
Rahmoune, Hakim
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (21):
[10] Immune-mediated inflammatory diseases and psoriasis
Delaporte, E.
ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2008, 135 : S269 - S274

← 1 2 3 4 5 →